A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)

Escalante, Agustin

Funded by

ELI LILLY & COMPANY

Research Start Date

11/01/2020

Status

Active

Collaborative Project

Clinical Care

Drug Discovery

Other

Bioscience Research Panel